Sydney, Feb 27, 2026, 17:25 AEDT — After-hours
CSL Limited settled 0.5% higher at A$146.76 Friday, having swung from A$145.07 to A$147.53 through the session as roughly 1.68 million shares traded. The stock finished just about A$2 clear of its 52-week low at A$144.61, according to data.
The significance was really in the absence of a fresh tumble. CSL has spent the past weeks searching for some stability after its half-year profit miss and a shake-up at the top earlier this month—interim chief Gordon Naylor summed it up for analysts: “I’m not prepared to accept that we can’t do better.” Reuters
The broader tone stayed upbeat, too. S&P/ASX 200 finished at a fresh record—9,198.60, up 0.25%.
CSL picked up 70,215 shares in Thursday’s buyback, shelling out A$10.25 million at prices ranging from A$145.18 to A$147.10, according to a filing. So far, the company’s bought back 3.70 million shares—roughly 0.8% of its issued stock—through its on-market program, snapping up its own shares directly on the exchange.
Macro factors haven’t taken center stage, but they’re in the mix. The Australian dollar edged up roughly 0.3% this day, putting it more than 6% higher for the year so far, according to Reuters. That type of gain pressures the translated earnings at companies like CSL, which have most of their business overseas.
Pipeline moves and deal flow remain in focus for CSL as the reset continues. Back in February, the company inked a deal giving Eli Lilly certain rights to clazakizumab, a monoclonal antibody drug candidate, pulling in a $100 million upfront payment. “Clazakizumab is a promising therapeutic candidate,” CSL’s R&D head Bill Mezzanotte said. Reuters
The recent change at the top hasn’t faded from investors’ minds. CSL announced in February that Paul McKenzie was out as chief executive. Chair Brian McNamee told the market that management and the board had “determined that now is the right time for new leadership.” Gordon Naylor has taken over as interim CEO. ABC News
Still, the buyback leaves the core debate over earnings momentum unresolved. Even with a steadier tape, things could unravel quickly if operating results in plasma, vaccines, or kidney-care don’t start to show progress.
What’s next? The interim dividend looms: CSL shares go ex-div on March 10, with March 11 as the record date and a payout slated for April 9. Full-year results land August 18.
Related articles: ASX:CSL
